Investing.com - Accolade reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Accolade announced earnings per share of $-0.66 on revenue of $87.64M. Analysts polled by Investing.com anticipated EPS of $-0.72 on revenue of $82.87M.
Accolade shares are down 53% from the beginning of the year and are trading at $11.92 , down-from-52-week-high.
Accolade shares lost 3.79% in after-hours trade the report.
Accolade follows other major Healthcare sector earnings this month
Accolade's report follows an earnings beat by Merck ADR on September 9, who reported EPS of $0.5392 on revenue of $5.69B, compared to forecasts EPS of $0.5165 on revenue of $5.57B.
Carl Zeiss Meditec ADR had beat expectations on September 9 with third quarter EPS of $0.7134 on revenue of $486.54M, compared to forecast for EPS of $0.7116 on revenue of $486.31M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar